Dr. Ho is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Molecular Genetic Pathology, 2015 - 2016
Brigham and Women's HospitalFellowship, Hematopathology, 2014 - 2015
Yale-New Haven Medical CenterResidency, Pathology-Anatomic and Clinical, 2010 - 2014
David Geffen School of Medicine at UCLAClass of 2008
Certifications & Licensure
MA State Medical License 2014 - 2026
NJ State Medical License 2021 - 2025
NY State Medical License 2016 - 2025- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Pathology - Hematology
- American Board of Pathology Pathology - Molecular Genetic
Publications & Presentations
PubMed
- 1 citationsto: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron
Haematologica. 2024-08-01 - 1 citationsImmunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron
Haematologica. 2024-04-01 - Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Detailed Descr...Kseniya Petrova-Drus, Mustafa Syed, Wayne Yu, Kasey Hutt, Alyssa M Zlotnicki
The Journal of Molecular Diagnostics. 2023-06-01
Abstracts/Posters
- Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology KnowledgebaseCaleb Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...Caleb Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...Caleb Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a Spike-in Clonal Sequence61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Professional Memberships
- Member
- Member
- Member
- Member
Other Languages
- Chinese (Cantonese)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
